Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Point-of-Care Testing » Spartan Bioscience Targeting Alzheimer's Drug Trials With New Near-Patient APOE Test

Spartan Bioscience Targeting Alzheimer's Drug Trials With New Near-Patient APOE Test

Jul 27, 2016
|
Madeleine Johnson
Premium

NEW YORK (GenomeWeb) – After launching the "world's smallest" PCR-based diagnostic device less than two months ago, Spartan Bioscience this week announced the first official test on the system — a 30-minute cheek swab assay for mutations in the apolipoprotein E (APOE) gene.

The target market for the research-use only test is pharmaceutical companies, to help focus and speed up Alzheimer's disease-related clinical trials, Spartan's CEO Paul Lem said in an interview.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Mix of Human and Monkey

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

Fetal Tissue Policy Changes Expected

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

Science Papers on Approach to Isolate DNA from Sediment, Algorithm to Construct Signaling Networks

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Sequencing the Zoo

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.

May
05
Featured Webinar

Establishing a Pharmacogenomic Service for Routine Clinical Care

Sponsored by
Illumina

Adverse drug reactions (ADRs) are responsible for around 5 percent of hospital admissions and occur in 6 percent to 15 percent of hospital stays.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.